Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients

201846 citationsJournal Article

Authors

Corentin Richard · Heat Transfer Research (United States)

Jean-David Fumet · Centre Georges François Leclerc

Sandy Chevrier · Transgene (France)

Valentin Dérangère · Transgene (France)

Fanny Ledys · Heat Transfer Research (United States)

Aurélie Lagrange · Centre Georges François Leclerc

Laure Favier

Abstract

Altogether, these data provide a validated biomarker that predicts the efficacy of nivolumab or pembrolizumab in patients with NSCLC. Our biomarker seems to be superior to PD-L1 labeling and TMB models.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 3, pp. 957-966

DOI: 10.1158/1078-0432.ccr-18-1940

Field-Weighted Citation Impact: 2.74